Relapsing-Remitting Multiple Sclerosis
Expert Insights on COVID-19 Prophylaxis in Patients With Multiple Sclerosis and Related Disorders
This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Treatment Options
Pathophysiology
Etiology and Risk Factors
Definition and Classification
Relapses reduced by 67% after 72 months with ozanimod in patients with multiple sclerosis
WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.
Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations
Supported by an educational grant from Biogen.
Ace the Case: A 52-Year-Old Woman With Gradual Walking Difficulties
There is no commercial support for this activity.
Diroximel fumarate linked to better outcomes compared with interferon in MS at 96 weeks
For those with relapsing-remitting MS, treatment with diroximel fumarate was linked to better outcomes at 96 weeks compared with those given interferon beta-1a, according to a presentation at ECTRIMS 2023.
COVID-19 linked to increased risk of physical disability progression in MS
In a cohort of individuals with MS, a diagnosis of COVID-19 was linked to an increased risk of disability progression compared with those without, according to a presentation from ECTRIMS 2023.